Immunological challenges for peptide-based immunotherapy in glioblastoma
Standard
Immunological challenges for peptide-based immunotherapy in glioblastoma. / Mohme, Malte; Neidert, Marian C; Regli, Luca; Weller, Michael; Martin, Roland.
In: CANCER TREAT REV, Vol. 40, No. 2, 03.2014, p. 248-58.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immunological challenges for peptide-based immunotherapy in glioblastoma
AU - Mohme, Malte
AU - Neidert, Marian C
AU - Regli, Luca
AU - Weller, Michael
AU - Martin, Roland
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2014/3
Y1 - 2014/3
N2 - Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15 months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.
AB - Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15 months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.
KW - Animals
KW - Antigens, Neoplasm
KW - Cancer Vaccines
KW - Central Nervous System Neoplasms
KW - Clinical Trials as Topic
KW - Glioblastoma
KW - Humans
KW - Immunosuppression
KW - Immunotherapy
KW - Peptides
KW - Journal Article
KW - Review
U2 - 10.1016/j.ctrv.2013.08.008
DO - 10.1016/j.ctrv.2013.08.008
M3 - SCORING: Journal article
C2 - 24064197
VL - 40
SP - 248
EP - 258
JO - CANCER TREAT REV
JF - CANCER TREAT REV
SN - 0305-7372
IS - 2
ER -